Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 12 | 2025 | 74 | 3.870 |
Why?
|
| Peanut Hypersensitivity | 9 | 2025 | 17 | 2.910 |
Why?
|
| Desensitization, Immunologic | 10 | 2025 | 43 | 2.200 |
Why?
|
| Asthma | 12 | 2022 | 1004 | 2.130 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2016 | 26 | 1.800 |
Why?
|
| Arachis | 7 | 2025 | 13 | 1.650 |
Why?
|
| Dust | 4 | 2017 | 26 | 1.520 |
Why?
|
| Allergens | 12 | 2025 | 189 | 1.250 |
Why?
|
| Environmental Exposure | 6 | 2017 | 340 | 0.990 |
Why?
|
| Anaphylaxis | 2 | 2023 | 33 | 0.920 |
Why?
|
| Hypersensitivity | 4 | 2021 | 164 | 0.910 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2022 | 48 | 0.890 |
Why?
|
| Insurance Claim Review | 1 | 2024 | 45 | 0.880 |
Why?
|
| Patient Preference | 1 | 2025 | 120 | 0.840 |
Why?
|
| Choice Behavior | 1 | 2025 | 163 | 0.840 |
Why?
|
| Health Expenditures | 1 | 2024 | 97 | 0.810 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2013 | 63 | 0.810 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2022 | 25 | 0.780 |
Why?
|
| Antigens, Plant | 2 | 2025 | 15 | 0.780 |
Why?
|
| Child, Preschool | 18 | 2025 | 3806 | 0.750 |
Why?
|
| Egg Hypersensitivity | 2 | 2019 | 4 | 0.750 |
Why?
|
| Child | 22 | 2024 | 7309 | 0.740 |
Why?
|
| Housing | 5 | 2015 | 47 | 0.730 |
Why?
|
| Allergy and Immunology | 1 | 2019 | 14 | 0.640 |
Why?
|
| Dermatitis, Atopic | 3 | 2024 | 62 | 0.570 |
Why?
|
| Poverty | 3 | 2016 | 189 | 0.560 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 167 | 0.550 |
Why?
|
| 2S Albumins, Plant | 1 | 2017 | 1 | 0.550 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 557 | 0.540 |
Why?
|
| Humans | 50 | 2025 | 92352 | 0.530 |
Why?
|
| Glycoproteins | 2 | 2017 | 233 | 0.520 |
Why?
|
| Environmental Monitoring | 3 | 2014 | 82 | 0.510 |
Why?
|
| Pandemics | 2 | 2021 | 807 | 0.500 |
Why?
|
| Microbiota | 2 | 2018 | 412 | 0.490 |
Why?
|
| Pediatrics | 1 | 2019 | 369 | 0.470 |
Why?
|
| Pyroglyphidae | 2 | 2013 | 15 | 0.440 |
Why?
|
| United States | 12 | 2025 | 7367 | 0.440 |
Why?
|
| Eczema | 1 | 2014 | 8 | 0.430 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 54 | 0.420 |
Why?
|
| Dietary Supplements | 1 | 2014 | 126 | 0.410 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 81 | 0.400 |
Why?
|
| Air Pollution, Indoor | 4 | 2014 | 65 | 0.370 |
Why?
|
| Angioedema | 1 | 2011 | 4 | 0.370 |
Why?
|
| Bacteria | 1 | 2015 | 500 | 0.360 |
Why?
|
| Plant Proteins | 2 | 2025 | 137 | 0.360 |
Why?
|
| Familial Mediterranean Fever | 1 | 2010 | 4 | 0.350 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 1 | 2010 | 2 | 0.350 |
Why?
|
| Stomatitis, Aphthous | 1 | 2010 | 4 | 0.350 |
Why?
|
| Pharyngitis | 1 | 2010 | 15 | 0.350 |
Why?
|
| Adolescent | 12 | 2025 | 9495 | 0.340 |
Why?
|
| Retrospective Studies | 7 | 2024 | 9694 | 0.330 |
Why?
|
| Female | 21 | 2025 | 47901 | 0.330 |
Why?
|
| Models, Theoretical | 1 | 2012 | 497 | 0.320 |
Why?
|
| Infant | 7 | 2025 | 3206 | 0.320 |
Why?
|
| Administration, Oral | 5 | 2022 | 670 | 0.320 |
Why?
|
| Smoking | 1 | 2013 | 640 | 0.320 |
Why?
|
| Medicaid | 2 | 2022 | 248 | 0.290 |
Why?
|
| Male | 18 | 2025 | 43929 | 0.290 |
Why?
|
| Rhinitis, Allergic | 2 | 2019 | 46 | 0.260 |
Why?
|
| Double-Blind Method | 4 | 2025 | 1755 | 0.250 |
Why?
|
| Immune Tolerance | 2 | 2019 | 360 | 0.240 |
Why?
|
| Epinephrine | 2 | 2021 | 89 | 0.220 |
Why?
|
| Food Supply | 2 | 2021 | 29 | 0.220 |
Why?
|
| Young Adult | 4 | 2025 | 6629 | 0.220 |
Why?
|
| Health Resources | 1 | 2024 | 80 | 0.210 |
Why?
|
| Air Microbiology | 2 | 2014 | 5 | 0.210 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1773 | 0.200 |
Why?
|
| Fungi | 2 | 2014 | 67 | 0.200 |
Why?
|
| Skin Tests | 1 | 2022 | 44 | 0.200 |
Why?
|
| Food | 2 | 2022 | 93 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 610 | 0.190 |
Why?
|
| Vocabulary, Controlled | 1 | 2022 | 13 | 0.190 |
Why?
|
| Albuterol | 1 | 2022 | 35 | 0.190 |
Why?
|
| Probiotics | 2 | 2024 | 90 | 0.190 |
Why?
|
| Early Diagnosis | 1 | 2022 | 130 | 0.190 |
Why?
|
| Food Assistance | 1 | 2021 | 8 | 0.190 |
Why?
|
| Data Collection | 1 | 2023 | 379 | 0.180 |
Why?
|
| Kansas | 3 | 2016 | 7 | 0.180 |
Why?
|
| Immunologic Factors | 1 | 2022 | 175 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1900 | 0.170 |
Why?
|
| Comorbidity | 1 | 2024 | 986 | 0.170 |
Why?
|
| Terminology as Topic | 2 | 2018 | 224 | 0.170 |
Why?
|
| Skin | 1 | 2024 | 595 | 0.170 |
Why?
|
| Prevalence | 2 | 2014 | 1298 | 0.160 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 34 | 0.160 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 15 | 0.160 |
Why?
|
| Egg Proteins, Dietary | 1 | 2019 | 1 | 0.160 |
Why?
|
| Machine Learning | 1 | 2022 | 299 | 0.160 |
Why?
|
| Allergists | 1 | 2018 | 4 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2020 | 99 | 0.150 |
Why?
|
| Adult | 9 | 2025 | 27547 | 0.150 |
Why?
|
| Prebiotics | 1 | 2018 | 8 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 111 | 0.150 |
Why?
|
| Fatty Acids, Volatile | 1 | 2018 | 36 | 0.150 |
Why?
|
| Hospitalization | 1 | 2024 | 925 | 0.150 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2506 | 0.140 |
Why?
|
| Middle Aged | 6 | 2025 | 27045 | 0.140 |
Why?
|
| Collagen Type V | 1 | 2017 | 3 | 0.140 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2017 | 9 | 0.140 |
Why?
|
| Skin Abnormalities | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aged | 4 | 2025 | 19953 | 0.140 |
Why?
|
| Eye Abnormalities | 1 | 2017 | 41 | 0.140 |
Why?
|
| Cross Reactions | 1 | 2017 | 110 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2730 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 24 | 0.130 |
Why?
|
| Joint Instability | 1 | 2017 | 91 | 0.130 |
Why?
|
| Disease Progression | 2 | 2020 | 1500 | 0.120 |
Why?
|
| Biological Products | 1 | 2018 | 171 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2016 | 67 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2014 | 694 | 0.120 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 52 | 0.120 |
Why?
|
| Genes, Bacterial | 1 | 2015 | 199 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 190 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 259 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 87 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 228 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 902 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 109 | 0.110 |
Why?
|
| Administration, Cutaneous | 2 | 2025 | 61 | 0.110 |
Why?
|
| Fish Oils | 1 | 2014 | 13 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 542 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 100 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 32 | 0.110 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2013 | 11 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 148 | 0.100 |
Why?
|
| Food Contamination | 1 | 2012 | 34 | 0.100 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 22 | 0.100 |
Why?
|
| Immune System | 1 | 2013 | 102 | 0.100 |
Why?
|
| Risk | 1 | 2014 | 661 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 253 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2016 | 679 | 0.090 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Angioedemas, Hereditary | 1 | 2011 | 2 | 0.090 |
Why?
|
| Complement C4 | 1 | 2011 | 8 | 0.090 |
Why?
|
| Animals | 6 | 2024 | 28059 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2013 | 97 | 0.090 |
Why?
|
| Urticaria | 1 | 2011 | 15 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 876 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 499 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2014 | 550 | 0.080 |
Why?
|
| Phylogeny | 1 | 2015 | 1231 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 886 | 0.080 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2009 | 6 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2009 | 20 | 0.080 |
Why?
|
| Family Practice | 1 | 2009 | 84 | 0.070 |
Why?
|
| Pregnancy | 1 | 2014 | 3113 | 0.060 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 369 | 0.060 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 69 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2006 | 58 | 0.060 |
Why?
|
| Bezoars | 1 | 2005 | 3 | 0.060 |
Why?
|
| Rubber | 1 | 2005 | 6 | 0.060 |
Why?
|
| Pica | 1 | 2005 | 14 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 125 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 91 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 148 | 0.060 |
Why?
|
| Epitopes | 1 | 2025 | 249 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2023 | 97 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2006 | 340 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2023 | 94 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 173 | 0.050 |
Why?
|
| Iowa | 1 | 2022 | 35 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 415 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 26 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2023 | 118 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 84 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 76 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2397 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 137 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2022 | 399 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2020 | 82 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 42 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 268 | 0.040 |
Why?
|
| beta-Thalassemia | 1 | 1997 | 5 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 290 | 0.030 |
Why?
|
| Joints | 1 | 2017 | 33 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 153 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 213 | 0.030 |
Why?
|
| Face | 1 | 2017 | 114 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 284 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 138 | 0.030 |
Why?
|
| Risk Factors | 3 | 2014 | 5708 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 179 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 44 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 54 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 4213 | 0.030 |
Why?
|
| Missouri | 1 | 2014 | 19 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2014 | 7 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1904 | 0.030 |
Why?
|
| Genes, Fungal | 1 | 2014 | 58 | 0.030 |
Why?
|
| Exome | 1 | 2014 | 134 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 52 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 475 | 0.030 |
Why?
|
| Arthropod Proteins | 1 | 2013 | 8 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1312 | 0.030 |
Why?
|
| United States Environmental Protection Agency | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cysteine Endopeptidases | 1 | 2013 | 86 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 556 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2012 | 58 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2013 | 142 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 248 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1138 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 8730 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1075 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 335 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 3776 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1920 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2979 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 924 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 863 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Air Conditioning | 1 | 2009 | 6 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 46 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 803 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 152 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2009 | 55 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 181 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 172 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 247 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2449 | 0.020 |
Why?
|
| Interior Design and Furnishings | 1 | 2005 | 1 | 0.020 |
Why?
|
| Illinois | 1 | 2006 | 502 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 903 | 0.010 |
Why?
|
| Boutonneuse Fever | 1 | 1983 | 1 | 0.010 |
Why?
|
| Rickettsiaceae Infections | 1 | 1983 | 2 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1983 | 71 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1926 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2368 | 0.010 |
Why?
|
| Prognosis | 2 | 2006 | 3872 | 0.010 |
Why?
|
| Siderosis | 1 | 1997 | 2 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Iron | 1 | 1997 | 175 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1016 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 6918 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 995 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 966 | 0.010 |
Why?
|
| Liver | 1 | 1997 | 1225 | 0.010 |
Why?
|
| Time Factors | 1 | 1997 | 5431 | 0.000 |
Why?
|